Replimune Group, Inc. (REPL) stock
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$21.98+0.20 (+0.92%)
Close on Nov 12, 2026Market cap $2.08BP/E –Yield –
Replimune revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $0 | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $0 | – |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $0 | – |
See a number that looks wrong?